JP2017529837A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017529837A5 JP2017529837A5 JP2017512760A JP2017512760A JP2017529837A5 JP 2017529837 A5 JP2017529837 A5 JP 2017529837A5 JP 2017512760 A JP2017512760 A JP 2017512760A JP 2017512760 A JP2017512760 A JP 2017512760A JP 2017529837 A5 JP2017529837 A5 JP 2017529837A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- group
- independently
- carbon atoms
- branched
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims description 89
- 102000036639 antigens Human genes 0.000 claims description 89
- 108091007433 antigens Proteins 0.000 claims description 89
- 125000004432 carbon atom Chemical group C* 0.000 claims description 84
- 125000000217 alkyl group Chemical group 0.000 claims description 53
- 125000003342 alkenyl group Chemical group 0.000 claims description 50
- 125000000304 alkynyl group Chemical group 0.000 claims description 48
- 229940127089 cytotoxic agent Drugs 0.000 claims description 47
- 239000002254 cytotoxic agent Substances 0.000 claims description 44
- 229910052757 nitrogen Inorganic materials 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 38
- 150000001875 compounds Chemical class 0.000 claims description 33
- 125000005842 heteroatom Chemical group 0.000 claims description 32
- 229910052717 sulfur Inorganic materials 0.000 claims description 32
- 229910052760 oxygen Inorganic materials 0.000 claims description 31
- 229920001223 polyethylene glycol Chemical group 0.000 claims description 31
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 30
- 229910052698 phosphorus Inorganic materials 0.000 claims description 30
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 28
- 210000004027 cell Anatomy 0.000 claims description 27
- 239000002202 Polyethylene glycol Substances 0.000 claims description 25
- -1 K + Chemical class 0.000 claims description 24
- 125000000623 heterocyclic group Chemical group 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 24
- 125000000539 amino acid group Chemical group 0.000 claims description 23
- 150000001413 amino acids Chemical class 0.000 claims description 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 20
- 229910052736 halogen Inorganic materials 0.000 claims description 20
- 150000002367 halogens Chemical class 0.000 claims description 20
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 20
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 18
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 claims description 18
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 17
- 125000003172 aldehyde group Chemical group 0.000 claims description 17
- 239000011230 binding agent Substances 0.000 claims description 17
- 125000001424 substituent group Chemical group 0.000 claims description 17
- 125000003118 aryl group Chemical group 0.000 claims description 16
- 125000001072 heteroaryl group Chemical group 0.000 claims description 16
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical group NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 15
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 15
- 108010056243 alanylalanine Proteins 0.000 claims description 15
- 125000003827 glycol group Chemical group 0.000 claims description 15
- 125000005647 linker group Chemical group 0.000 claims description 15
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 claims description 14
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 13
- 125000004043 oxo group Chemical group O=* 0.000 claims description 13
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 12
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 12
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 12
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- KWEDUNSJJZVRKR-UHFFFAOYSA-N carbononitridic azide Chemical compound [N-]=[N+]=NC#N KWEDUNSJJZVRKR-UHFFFAOYSA-N 0.000 claims description 12
- 239000001301 oxygen Substances 0.000 claims description 12
- 239000011593 sulfur Substances 0.000 claims description 12
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 11
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 10
- 239000004473 Threonine Substances 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 125000006242 amine protecting group Chemical group 0.000 claims description 9
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 125000003107 substituted aryl group Chemical group 0.000 claims description 9
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 claims description 8
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- ZVDGZUVHJGGWSG-BKLSDQPFSA-N (2s)-2,5-diamino-4-hydroxypentanoic acid Chemical compound NCC(O)C[C@H](N)C(O)=O ZVDGZUVHJGGWSG-BKLSDQPFSA-N 0.000 claims description 7
- DEFJQIDDEAULHB-QWWZWVQMSA-N D-alanyl-D-alanine Chemical compound C[C@@H]([NH3+])C(=O)N[C@H](C)C([O-])=O DEFJQIDDEAULHB-QWWZWVQMSA-N 0.000 claims description 7
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 claims description 7
- DEFJQIDDEAULHB-UHFFFAOYSA-N N-D-alanyl-D-alanine Natural products CC(N)C(=O)NC(C)C(O)=O DEFJQIDDEAULHB-UHFFFAOYSA-N 0.000 claims description 7
- KUBJJRKPDYRKIP-UHFFFAOYSA-N NC(C(=O)O)CC(CO)N Chemical group NC(C(=O)O)CC(CO)N KUBJJRKPDYRKIP-UHFFFAOYSA-N 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 claims description 7
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 claims description 7
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 claims description 7
- 108091033319 polynucleotide Proteins 0.000 claims description 7
- 102000040430 polynucleotide Human genes 0.000 claims description 7
- 239000002157 polynucleotide Substances 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 239000007800 oxidant agent Substances 0.000 claims description 6
- KQRHTCDQWJLLME-XUXIUFHCSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)N KQRHTCDQWJLLME-XUXIUFHCSA-N 0.000 claims description 5
- AGGWFDNPHKLBBV-YUMQZZPRSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoic acid Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=O AGGWFDNPHKLBBV-YUMQZZPRSA-N 0.000 claims description 5
- ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 claims description 5
- RVLOMLVNNBWRSR-KNIFDHDWSA-N (2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O RVLOMLVNNBWRSR-KNIFDHDWSA-N 0.000 claims description 5
- WEZDRVHTDXTVLT-GJZGRUSLSA-N 2-[[(2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 WEZDRVHTDXTVLT-GJZGRUSLSA-N 0.000 claims description 5
- LIWMQSWFLXEGMA-WDSKDSINSA-N Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)N LIWMQSWFLXEGMA-WDSKDSINSA-N 0.000 claims description 5
- OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 claims description 5
- DAQIJMOLTMGJLO-YUMQZZPRSA-N Arg-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCNC(N)=N DAQIJMOLTMGJLO-YUMQZZPRSA-N 0.000 claims description 5
- 102100035139 Folate receptor alpha Human genes 0.000 claims description 5
- 108010009504 Gly-Phe-Leu-Gly Proteins 0.000 claims description 5
- YLEIWGJJBFBFHC-KBPBESRZSA-N Gly-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 YLEIWGJJBFBFHC-KBPBESRZSA-N 0.000 claims description 5
- 101001023230 Homo sapiens Folate receptor alpha Proteins 0.000 claims description 5
- VAXBXNPRXPHGHG-BJDJZHNGSA-N Ile-Ala-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)O)N VAXBXNPRXPHGHG-BJDJZHNGSA-N 0.000 claims description 5
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 claims description 5
- LSPYFSHXDAYVDI-SRVKXCTJSA-N Leu-Ala-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(C)C LSPYFSHXDAYVDI-SRVKXCTJSA-N 0.000 claims description 5
- NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 claims description 5
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims description 5
- MIDZLCFIAINOQN-WPRPVWTQSA-N Phe-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 MIDZLCFIAINOQN-WPRPVWTQSA-N 0.000 claims description 5
- RBRNEFJTEHPDSL-ACRUOGEOSA-N Phe-Phe-Lys Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 RBRNEFJTEHPDSL-ACRUOGEOSA-N 0.000 claims description 5
- QRZVUAAKNRHEOP-GUBZILKMSA-N Val-Ala-Val Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O QRZVUAAKNRHEOP-GUBZILKMSA-N 0.000 claims description 5
- IBIDRSSEHFLGSD-YUMQZZPRSA-N Val-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IBIDRSSEHFLGSD-YUMQZZPRSA-N 0.000 claims description 5
- JKHXYJKMNSSFFL-IUCAKERBSA-N Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN JKHXYJKMNSSFFL-IUCAKERBSA-N 0.000 claims description 5
- 108010054982 alanyl-leucyl-alanyl-leucine Proteins 0.000 claims description 5
- 125000002947 alkylene group Chemical group 0.000 claims description 5
- 108010068380 arginylarginine Proteins 0.000 claims description 5
- 108010036533 arginylvaline Proteins 0.000 claims description 5
- 150000001768 cations Chemical class 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 108010054155 lysyllysine Proteins 0.000 claims description 5
- 230000001590 oxidative effect Effects 0.000 claims description 5
- 108010024607 phenylalanylalanine Proteins 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 125000006850 spacer group Chemical group 0.000 claims description 5
- IBIDRSSEHFLGSD-UHFFFAOYSA-N valinyl-arginine Natural products CC(C)C(N)C(=O)NC(C(O)=O)CCCN=C(N)N IBIDRSSEHFLGSD-UHFFFAOYSA-N 0.000 claims description 5
- 108010073969 valyllysine Proteins 0.000 claims description 5
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 claims description 4
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 239000002131 composite material Substances 0.000 claims description 4
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 claims description 4
- GRWZHXKQBITJKP-UHFFFAOYSA-L dithionite(2-) Chemical compound [O-]S(=O)S([O-])=O GRWZHXKQBITJKP-UHFFFAOYSA-L 0.000 claims description 4
- 229940017705 formaldehyde sulfoxylate Drugs 0.000 claims description 4
- 208000024908 graft versus host disease Diseases 0.000 claims description 4
- SBGKURINHGJRFN-UHFFFAOYSA-N hydroxymethanesulfinic acid Chemical compound OCS(O)=O SBGKURINHGJRFN-UHFFFAOYSA-N 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 230000003647 oxidation Effects 0.000 claims description 4
- 238000007254 oxidation reaction Methods 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- HSRXSKHRSXRCFC-WDSKDSINSA-N Val-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(O)=O HSRXSKHRSXRCFC-WDSKDSINSA-N 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 125000005717 substituted cycloalkylene group Chemical group 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 208000020084 Bone disease Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims description 2
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 2
- 206010061598 Immunodeficiency Diseases 0.000 claims description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 2
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims description 2
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 claims description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 2
- 201000002481 Myositis Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 125000004450 alkenylene group Chemical group 0.000 claims description 2
- 125000004419 alkynylene group Chemical group 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 125000005724 cycloalkenylene group Chemical group 0.000 claims description 2
- 230000001066 destructive effect Effects 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 150000004820 halides Chemical class 0.000 claims description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 2
- 230000007813 immunodeficiency Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000002628 peritoneum cancer Diseases 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 claims description 2
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 2
- 229940124530 sulfonamide Drugs 0.000 claims description 2
- 150000003456 sulfonamides Chemical class 0.000 claims description 2
- 150000003462 sulfoxides Chemical class 0.000 claims description 2
- 125000001302 tertiary amino group Chemical group 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 claims 2
- 230000010261 cell growth Effects 0.000 claims 1
- 150000003457 sulfones Chemical class 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 description 19
- 235000001014 amino acid Nutrition 0.000 description 19
- 0 Cc1c(C[C@@](C(*)=Cc2c3cc(*)c(*Cc(cc4C*c(c(*)c5)cc(C(*)CC(*)[C@](C6)N7c8c6c(*)c(*)c(*)c8*)c5C7=O)c(C)c(I)c4I)c2)N2C3=O)c2c(*=C)c(C)c1C Chemical compound Cc1c(C[C@@](C(*)=Cc2c3cc(*)c(*Cc(cc4C*c(c(*)c5)cc(C(*)CC(*)[C@](C6)N7c8c6c(*)c(*)c(*)c8*)c5C7=O)c(C)c(I)c4I)c2)N2C3=O)c2c(*=C)c(C)c1C 0.000 description 17
- 229910006069 SO3H Inorganic materials 0.000 description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 229910004727 OSO3H Inorganic materials 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- 239000004365 Protease Substances 0.000 description 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 4
- BYXHQQCXAJARLQ-ZLUOBGJFSA-N Ala-Ala-Ala Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O BYXHQQCXAJARLQ-ZLUOBGJFSA-N 0.000 description 4
- SOTXLXCVCZAKFI-FXQIFTODSA-N Ala-Val-Ala Chemical compound C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O SOTXLXCVCZAKFI-FXQIFTODSA-N 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- AXDLCFOOGCNDST-UHFFFAOYSA-N N-Methyltyrosine Chemical compound CNC(C(O)=O)CC1=CC=C(O)C=C1 AXDLCFOOGCNDST-UHFFFAOYSA-N 0.000 description 4
- KSPIYJQBLVDRRI-UHFFFAOYSA-N N-methylisoleucine Chemical compound CCC(C)C(NC)C(O)=O KSPIYJQBLVDRRI-UHFFFAOYSA-N 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 108010017893 alanyl-alanyl-alanine Proteins 0.000 description 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine group Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 101100476210 Caenorhabditis elegans rnt-1 gene Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000003432 anti-folate effect Effects 0.000 description 3
- 229940127074 antifolate Drugs 0.000 description 3
- 239000004052 folic acid antagonist Substances 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- DVOOXRTYGGLORL-VKHMYHEASA-N (2r)-2-(methylamino)-3-sulfanylpropanoic acid Chemical compound CN[C@@H](CS)C(O)=O DVOOXRTYGGLORL-VKHMYHEASA-N 0.000 description 2
- HOKKHZGPKSLGJE-VKHMYHEASA-N (2s)-2-(methylamino)butanedioic acid Chemical compound CN[C@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-VKHMYHEASA-N 0.000 description 2
- KEZRWUUMKVVUPT-BYPYZUCNSA-N (2s)-2-amino-3-(dimethylamino)propanoic acid Chemical compound CN(C)C[C@H](N)C(O)=O KEZRWUUMKVVUPT-BYPYZUCNSA-N 0.000 description 2
- LNSMPSPTFDIWRQ-VKHMYHEASA-N (2s)-4-amino-2-(methylamino)-4-oxobutanoic acid Chemical compound CN[C@H](C(O)=O)CC(N)=O LNSMPSPTFDIWRQ-VKHMYHEASA-N 0.000 description 2
- XJODGRWDFZVTKW-LURJTMIESA-N (2s)-4-methyl-2-(methylamino)pentanoic acid Chemical compound CN[C@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-LURJTMIESA-N 0.000 description 2
- CCAIIPMIAFGKSI-DMTCNVIQSA-N (2s,3r)-3-hydroxy-2-(methylazaniumyl)butanoate Chemical compound CN[C@@H]([C@@H](C)O)C(O)=O CCAIIPMIAFGKSI-DMTCNVIQSA-N 0.000 description 2
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 2
- XVQRABGSXSUQLJ-UHFFFAOYSA-N 2-amino-4-(dimethylamino)butanoic acid Chemical compound CN(C)CCC(N)C(O)=O XVQRABGSXSUQLJ-UHFFFAOYSA-N 0.000 description 2
- UGQZFFGZKJEVIY-UHFFFAOYSA-N 2-amino-5-(dimethylamino)pentanoic acid Chemical compound CN(C)CCCC(N)C(O)=O UGQZFFGZKJEVIY-UHFFFAOYSA-N 0.000 description 2
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 2
- ADVPTQAUNPRNPO-REOHCLBHSA-N 3-sulfino-L-alanine Chemical compound OC(=O)[C@@H](N)C[S@@](O)=O ADVPTQAUNPRNPO-REOHCLBHSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
- XVOYSCVBGLVSOL-REOHCLBHSA-N L-cysteic acid Chemical compound OC(=O)[C@@H](N)CS(O)(=O)=O XVOYSCVBGLVSOL-REOHCLBHSA-N 0.000 description 2
- XVOYSCVBGLVSOL-UHFFFAOYSA-N L-cysteine sulfonic acid Natural products OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 2
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- ONXPDKGXOOORHB-BYPYZUCNSA-N N(5)-methyl-L-glutamine Chemical compound CNC(=O)CC[C@H](N)C(O)=O ONXPDKGXOOORHB-BYPYZUCNSA-N 0.000 description 2
- PQNASZJZHFPQLE-UHFFFAOYSA-N N(6)-methyllysine Chemical compound CNCCCCC(N)C(O)=O PQNASZJZHFPQLE-UHFFFAOYSA-N 0.000 description 2
- CYZKJBZEIFWZSR-LURJTMIESA-N N(alpha)-methyl-L-histidine Chemical compound CN[C@H](C(O)=O)CC1=CNC=N1 CYZKJBZEIFWZSR-LURJTMIESA-N 0.000 description 2
- SCIFESDRCALIIM-UHFFFAOYSA-N N-Me-Phenylalanine Natural products CNC(C(O)=O)CC1=CC=CC=C1 SCIFESDRCALIIM-UHFFFAOYSA-N 0.000 description 2
- NTWVQPHTOUKMDI-YFKPBYRVSA-N N-Methyl-arginine Chemical compound CN[C@H](C(O)=O)CCCN=C(N)N NTWVQPHTOUKMDI-YFKPBYRVSA-N 0.000 description 2
- PSFABYLDRXJYID-VKHMYHEASA-N N-Methylserine Chemical compound CN[C@@H](CO)C(O)=O PSFABYLDRXJYID-VKHMYHEASA-N 0.000 description 2
- HOKKHZGPKSLGJE-UHFFFAOYSA-N N-methyl-D-aspartic acid Natural products CNC(C(O)=O)CC(O)=O HOKKHZGPKSLGJE-UHFFFAOYSA-N 0.000 description 2
- PSFABYLDRXJYID-UHFFFAOYSA-N N-methyl-DL-serine Natural products CNC(CO)C(O)=O PSFABYLDRXJYID-UHFFFAOYSA-N 0.000 description 2
- GDFAOVXKHJXLEI-VKHMYHEASA-N N-methyl-L-alanine Chemical compound C[NH2+][C@@H](C)C([O-])=O GDFAOVXKHJXLEI-VKHMYHEASA-N 0.000 description 2
- XLBVNMSMFQMKEY-BYPYZUCNSA-N N-methyl-L-glutamic acid Chemical compound CN[C@H](C(O)=O)CCC(O)=O XLBVNMSMFQMKEY-BYPYZUCNSA-N 0.000 description 2
- YAXAFCHJCYILRU-YFKPBYRVSA-N N-methyl-L-methionine Chemical compound C[NH2+][C@H](C([O-])=O)CCSC YAXAFCHJCYILRU-YFKPBYRVSA-N 0.000 description 2
- SCIFESDRCALIIM-VIFPVBQESA-N N-methyl-L-phenylalanine Chemical compound C[NH2+][C@H](C([O-])=O)CC1=CC=CC=C1 SCIFESDRCALIIM-VIFPVBQESA-N 0.000 description 2
- CWLQUGTUXBXTLF-UHFFFAOYSA-N N-methyl-L-proline monohydrate Natural products CN1CCCC1C(O)=O CWLQUGTUXBXTLF-UHFFFAOYSA-N 0.000 description 2
- AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 2
- CWLQUGTUXBXTLF-YFKPBYRVSA-N N-methylproline Chemical compound CN1CCC[C@H]1C(O)=O CWLQUGTUXBXTLF-YFKPBYRVSA-N 0.000 description 2
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 2
- XXEWFEBMSGLYBY-UHFFFAOYSA-N Ne,Ne dimethyllysine Chemical compound CN(C)CCCCC(N)C(O)=O XXEWFEBMSGLYBY-UHFFFAOYSA-N 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- 229910018823 PO2S2 Inorganic materials 0.000 description 2
- 229910018828 PO3H2 Inorganic materials 0.000 description 2
- 229910019250 POS3 Inorganic materials 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical compound OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- ADVPTQAUNPRNPO-UHFFFAOYSA-N alpha-amino-beta-sulfino-propionic acid Natural products OC(=O)C(N)CS(O)=O ADVPTQAUNPRNPO-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 229940000635 beta-alanine Drugs 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- UHBYWPGGCSDKFX-UHFFFAOYSA-N carboxyglutamic acid Chemical compound OC(=O)C(N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000013477 citrulline Nutrition 0.000 description 2
- 229960002173 citrulline Drugs 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 230000002132 lysosomal effect Effects 0.000 description 2
- LSDPWZHWYPCBBB-UHFFFAOYSA-O methylsulfide anion Chemical compound [SH2+]C LSDPWZHWYPCBBB-UHFFFAOYSA-O 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- QXHDYMUPPXAMPQ-UHFFFAOYSA-N 2-(4-aminophenyl)ethanol Chemical group NC1=CC=C(CCO)C=C1 QXHDYMUPPXAMPQ-UHFFFAOYSA-N 0.000 description 1
- DEDHGJRRQDQDKF-UHFFFAOYSA-N CC(C)CC(NC(CSC(C)C)C(O)=O)=O Chemical compound CC(C)CC(NC(CSC(C)C)C(O)=O)=O DEDHGJRRQDQDKF-UHFFFAOYSA-N 0.000 description 1
- VRZKVSKELFLXON-UHFFFAOYSA-N CC(C)NC(C(C)NC(C(C)NC(CCCC(C)=O)=O)=O)=O Chemical compound CC(C)NC(C(C)NC(C(C)NC(CCCC(C)=O)=O)=O)=O VRZKVSKELFLXON-UHFFFAOYSA-N 0.000 description 1
- XOVULDKOTPBNEY-UHFFFAOYSA-N CCC(NCC(NCC(NCC(C(C)C)=O)=O)=O)=O Chemical compound CCC(NCC(NCC(NCC(C(C)C)=O)=O)=O)=O XOVULDKOTPBNEY-UHFFFAOYSA-N 0.000 description 1
- OKBSQXZHPMPSFN-UHFFFAOYSA-N CCC(NCCNC(C(C)NC(C(C)NC(C(C)NC(COCC(C)=O)=O)=O)=O)=O)=O Chemical compound CCC(NCCNC(C(C)NC(C(C)NC(C(C)NC(COCC(C)=O)=O)=O)=O)=O)=O OKBSQXZHPMPSFN-UHFFFAOYSA-N 0.000 description 1
- CKXHHQSSQIMGIF-YYULCGAYSA-N C[C@@H](C(O[C@@H](CC(N(C)c1cc(C/C(/C)=C/C=C/C(C(C2)N3)OC)cc(OC)c1Cl)=O)[C@]1(C)O[C@H]1[C@H](C)[C@H]2OC3=O)=O)N(C)C(CCC(C)(C)SC)=O Chemical compound C[C@@H](C(O[C@@H](CC(N(C)c1cc(C/C(/C)=C/C=C/C(C(C2)N3)OC)cc(OC)c1Cl)=O)[C@]1(C)O[C@H]1[C@H](C)[C@H]2OC3=O)=O)N(C)C(CCC(C)(C)SC)=O CKXHHQSSQIMGIF-YYULCGAYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 229930193936 anticarin Natural products 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- QDHYJVJAGQLHBA-UHFFFAOYSA-N beta-Ala-Gly Chemical compound NCCC(=O)NCC(O)=O QDHYJVJAGQLHBA-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462045264P | 2014-09-03 | 2014-09-03 | |
| US62/045,264 | 2014-09-03 | ||
| US201462086986P | 2014-12-03 | 2014-12-03 | |
| US62/086,986 | 2014-12-03 | ||
| US201562149379P | 2015-04-17 | 2015-04-17 | |
| US62/149,379 | 2015-04-17 | ||
| US201562186235P | 2015-06-29 | 2015-06-29 | |
| US62/186,235 | 2015-06-29 | ||
| PCT/US2015/048044 WO2016036794A1 (en) | 2014-09-03 | 2015-09-02 | Conjugates comprising cell-binding agents and cytotoxic agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017529837A JP2017529837A (ja) | 2017-10-12 |
| JP2017529837A5 true JP2017529837A5 (OSRAM) | 2018-10-11 |
Family
ID=54147280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017512760A Pending JP2017529837A (ja) | 2014-09-03 | 2015-09-02 | 細胞結合剤及び細胞毒性剤を含む複合体 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10988531B2 (OSRAM) |
| EP (1) | EP3188733B1 (OSRAM) |
| JP (1) | JP2017529837A (OSRAM) |
| KR (3) | KR20240027148A (OSRAM) |
| CN (1) | CN107580604A (OSRAM) |
| AU (1) | AU2015312075A1 (OSRAM) |
| CA (1) | CA2957964A1 (OSRAM) |
| IL (1) | IL250711A0 (OSRAM) |
| MA (1) | MA40415A (OSRAM) |
| RU (1) | RU2017110068A (OSRAM) |
| SG (2) | SG11201701565PA (OSRAM) |
| TW (1) | TW201609152A (OSRAM) |
| WO (1) | WO2016036794A1 (OSRAM) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160058884A1 (en) * | 2014-09-02 | 2016-03-03 | Immunogen, Inc. | Methods for formulating antibody drug conjugate compositions |
| TW201609152A (zh) | 2014-09-03 | 2016-03-16 | 免疫原公司 | 包含細胞結合劑及細胞毒性劑之偶聯物 |
| TW202417447A (zh) * | 2014-09-03 | 2024-05-01 | 美商免疫原公司 | 細胞毒性苯并二氮呯衍生物 |
| AU2016215049B2 (en) | 2015-02-06 | 2021-12-02 | Cell Idx, Inc. | Antigen-coupled immunoreagents |
| LT3313884T (lt) * | 2015-06-29 | 2021-03-10 | Immunogen, Inc. | Anti-cd123 antikūnai, konjugatai ir jų dariniai |
| EP3653628B1 (en) * | 2015-07-21 | 2022-09-14 | ImmunoGen, Inc. | Methods of preparing cytotoxic benzodiazepine derivatives |
| CN108883196A (zh) * | 2016-02-05 | 2018-11-23 | 米伦纽姆医药公司 | 靶向gcc的抗体－药物缀合物 |
| TWI750194B (zh) * | 2016-07-05 | 2021-12-21 | 大陸商江蘇恆瑞醫藥股份有限公司 | Ｅｇｆｒ抗體-藥物偶聯物及其在醫藥上的應用 |
| CN109475639A (zh) | 2016-07-22 | 2019-03-15 | 尼克塔治疗公司 | 具有含肟键联的因子viii部分的轭合物 |
| MA46779A (fr) * | 2016-11-02 | 2019-09-11 | Health Research Inc | Traitement combiné avec des conjugués anticorps-médicament et des inhibiteurs de parp |
| CN118562004A (zh) | 2016-12-16 | 2024-08-30 | 蓝鳍生物医药公司 | 抗-含cub结构域蛋白1(cdcp1)抗体、抗体药物缀合物及其使用方法 |
| CN110267685B (zh) * | 2016-12-23 | 2023-06-20 | 伊缪诺金公司 | 靶向adam9的免疫缀合物及其使用方法 |
| IL298414B2 (en) | 2017-02-28 | 2024-12-01 | Immunogen Inc | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof |
| WO2018183494A1 (en) * | 2017-03-31 | 2018-10-04 | Immunogen, Inc. | Cd19-targeting antibody-drug conjugates |
| WO2019018892A1 (en) | 2017-07-26 | 2019-01-31 | The University Of Queensland | COMPOUNDS CONTAINING DISULFIDE BOND AND USES THEREOF |
| AU2018342527B2 (en) | 2017-09-29 | 2024-06-27 | Daiichi Sankyo Company, Limited | Antibody-pyrrolobenzodiazepine derivative conjugate |
| US20200362054A1 (en) * | 2017-11-21 | 2020-11-19 | Brian Granda | Trispecific binding molecules against tumor-associated antigents and use thereof |
| US11274121B2 (en) * | 2018-01-12 | 2022-03-15 | Immunogen, Inc. | Methods for antibody drug conjugation, purification, and formulation |
| KR102808710B1 (ko) | 2018-03-13 | 2025-05-15 | 페인스 테라퓨틱스 인코포레이티드 | 항-폴레이트 수용체 1 항체 및 이의 용도 |
| CA3105415A1 (en) * | 2018-07-09 | 2020-01-23 | Multitude Inc. | Antibodies specific to folate receptor alpha |
| WO2020060944A1 (en) * | 2018-09-17 | 2020-03-26 | Sutro Biopharma, Inc. | Combination therapies with anti-folate receptor antibody conjugates |
| TWI897855B (zh) * | 2018-10-26 | 2025-09-21 | 美商免疫遺傳股份有限公司 | Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途 |
| WO2020092631A1 (en) * | 2018-10-31 | 2020-05-07 | Fred Hutchinson Cancer Research Center | Compositions and methods for detecting and treating cancers characterized by expression of mesothelin |
| US20210032285A1 (en) * | 2019-03-11 | 2021-02-04 | Cell Idx, Inc. | Methods, compositions, and kits for trapping modified biomolecules |
| WO2020187998A1 (en) | 2019-03-19 | 2020-09-24 | Fundació Privada Institut D'investigació Oncològica De Vall Hebron | Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer |
| KR20220022112A (ko) * | 2019-03-21 | 2022-02-24 | 이뮤노젠 아이엔씨 | 세포-결합 제제-약물 콘쥬게이트를 준비하는 방법 |
| EP3972998A1 (en) | 2019-05-21 | 2022-03-30 | Novartis AG | Cd19 binding molecules and uses thereof |
| EP3972993A1 (en) | 2019-05-21 | 2022-03-30 | Novartis AG | Variant cd58 domains and uses thereof |
| EP4041718A4 (en) | 2019-10-10 | 2023-12-20 | Cellectar Biosciences, Inc. | PHOSPHOLIPIDE-FLVAGLIN CONJUGATES AND METHOD FOR THE USE THEREOF FOR TARGETED CANCER THERAPY |
| CN110922482B (zh) * | 2019-12-25 | 2021-08-31 | 源道隆（苏州）医学科技有限公司 | 可结合cd19的多肽及其应用 |
| CN112794911B (zh) * | 2021-04-14 | 2021-08-03 | 上海偌妥生物科技有限公司 | 人源化抗叶酸受体1抗体及其应用 |
| CN113908589B (zh) * | 2021-10-08 | 2022-09-27 | 天津工业大学 | 一种表面印迹抗体的疏水电荷诱导模式膜层析介质及其制备方法 |
| KR20250089547A (ko) | 2022-10-25 | 2025-06-18 | 펩토믹, 에스.엘. | 암 치료를 위한 조합 요법 |
| EP4473974A1 (en) | 2023-06-07 | 2024-12-11 | Peptomyc, S.L. | Omomyc and kras inhibitors combination therapy for the treatment of cancer |
| TW202502371A (zh) | 2023-06-07 | 2025-01-16 | 瓦爾希伯倫私人腫瘤研究基金會 | 用於治療癌症的與ｂｒａｆ抑制劑的組合療法 |
| WO2024251846A1 (en) | 2023-06-07 | 2024-12-12 | Fundació Privada Institut D'investigació Oncològica De Vall Hebron | Combination therapy with mek inhibitors for the treatment of cancer |
| CN117659041A (zh) * | 2023-12-08 | 2024-03-08 | 联宁（苏州）生物制药有限公司 | 用于抗体偶联药物的氘代蒽环类毒素连接子及其合成方法和应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5362852A (en) * | 1991-09-27 | 1994-11-08 | Pfizer Inc. | Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties |
| FR2801904B1 (fr) | 1999-12-07 | 2002-02-08 | Pasteur Institut | Produits comprenant un support sur lequel sont fixes des acides nucleiques et leur utilisation comme puce a adn |
| CA2499496C (fr) | 2002-09-19 | 2012-04-24 | Centre National De La Recherche Scientifique - Cnrs | Synthese et caracterisation de nouveaux systemes de guidage et de vectorisation de molecules d'interet therapeutique vers des cellules cibles |
| EP1667708B9 (en) | 2002-12-26 | 2012-10-31 | Mountain View Pharmaceuticals, Inc. | POLYETHYLENE GLYCOL CONJUGATES OF INTERFERON-BETA-1b WITH ENHANCED IN VITRO BIOLOGICAL POTENCY |
| GB0305704D0 (en) | 2003-03-13 | 2003-04-16 | Amersham Plc | Radiofluorination methods |
| BRPI0510883B8 (pt) | 2004-06-01 | 2021-05-25 | Genentech Inc | composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação |
| EP1805216A2 (en) | 2004-10-18 | 2007-07-11 | Novo Nordisk A/S | Growth hormone conjugates |
| JP5517450B2 (ja) | 2005-03-10 | 2014-06-11 | バイオンテック アーゲー | 二量体または多量体のマイクロタンパク質 |
| EP1877100A2 (en) | 2005-04-25 | 2008-01-16 | GE Healthcare AS | Liposomes |
| JP4938263B2 (ja) * | 2005-08-19 | 2012-05-23 | 独立行政法人農業生物資源研究所 | 一本鎖抗体によるサイトゾルタンパク質の機能阻害法およびその利用 |
| JP2009512443A (ja) | 2005-10-20 | 2009-03-26 | ザ スクリップス リサーチ インスチチュート | 免疫染色及び免疫標的化のためのＦｃ標識化 |
| FR2897616B1 (fr) | 2006-02-20 | 2008-05-30 | Univ Grenoble 1 | Presentation de motifs de reconnaissance par une matrice multivalente greffee sur un support solide |
| US7985783B2 (en) * | 2006-09-21 | 2011-07-26 | The Regents Of The University Of California | Aldehyde tags, uses thereof in site-specific protein modification |
| CL2008002085A1 (es) | 2007-07-16 | 2008-11-21 | Genentech Inc | Anticuerpo humanizado anti-cd79b/igbeta/b29; polinucleotido codificacnte, vector, celula huesped; metodo de fabricacion; inmunoconjugado; composicion farmaceutica; uso para tratar cancer; metodo in vitro para determinar presencia de cd79b, oinhibir crecimiento de celulas quqe expresa cd79b; ensayo in vitro para detectar celulas b |
| SI2211904T1 (sl) | 2007-10-19 | 2016-12-30 | Seattle Genetics, Inc. | CD19 vezavna sredstva in njihove uporabe |
| WO2009059278A1 (en) | 2007-11-02 | 2009-05-07 | Centocor, Inc. | Semi-synthetic glp-1 peptide-fc fusion constructs, methods and uses |
| MX2010011808A (es) | 2008-04-30 | 2011-03-04 | Immunogen Inc | Conjugados potentes y enlazadores hidrofilicos. |
| KR20230044026A (ko) * | 2010-02-24 | 2023-03-31 | 이뮤노젠 아이엔씨 | 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도 |
| US9381058B2 (en) * | 2010-11-05 | 2016-07-05 | Ethicon Endo-Surgery, Llc | Recharge system for medical devices |
| EP2675479B1 (en) * | 2011-02-15 | 2016-01-13 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
| US9056910B2 (en) | 2012-05-01 | 2015-06-16 | Genentech, Inc. | Anti-PMEL17 antibodies and immunoconjugates |
| MX369626B (es) * | 2012-05-24 | 2019-11-13 | Mountgate Group Ltd | Composiciones y metodos relacionados con la prevencion y el tratamiento de infecciones por rabia. |
| WO2013182661A1 (en) | 2012-06-06 | 2013-12-12 | Bionor Immuno As | Peptides derived from viral proteins for use as immunogens and dosage reactants |
| US9834597B2 (en) | 2012-09-21 | 2017-12-05 | The Regents Of The University Of California | Modified FC polypeptides, FC conjugates, and methods of use thereof |
| CN105051923B (zh) * | 2013-03-28 | 2017-12-01 | 东芝北斗电子株式会社 | 发光装置及其制造方法 |
| US9636404B2 (en) | 2013-05-13 | 2017-05-02 | Vision Global Holdings Ltd. | Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging |
| LT3038650T (lt) * | 2013-08-30 | 2021-09-10 | Immunogen, Inc. | Antikūnai ir foliatų receptoriaus 1 nustatymo testai |
| WO2015079376A1 (en) | 2013-11-26 | 2015-06-04 | Novartis Ag | Methods for oxime conjugation to ketone-modified polypeptides |
| TW201609152A (zh) | 2014-09-03 | 2016-03-16 | 免疫原公司 | 包含細胞結合劑及細胞毒性劑之偶聯物 |
-
2015
- 2015-09-02 TW TW104128984A patent/TW201609152A/zh unknown
- 2015-09-02 JP JP2017512760A patent/JP2017529837A/ja active Pending
- 2015-09-02 CN CN201580059534.4A patent/CN107580604A/zh active Pending
- 2015-09-02 MA MA040415A patent/MA40415A/fr unknown
- 2015-09-02 SG SG11201701565PA patent/SG11201701565PA/en unknown
- 2015-09-02 RU RU2017110068A patent/RU2017110068A/ru not_active Application Discontinuation
- 2015-09-02 SG SG10201901825YA patent/SG10201901825YA/en unknown
- 2015-09-02 EP EP15766288.3A patent/EP3188733B1/en active Active
- 2015-09-02 CA CA2957964A patent/CA2957964A1/en not_active Abandoned
- 2015-09-02 KR KR1020247005372A patent/KR20240027148A/ko active Pending
- 2015-09-02 US US14/843,429 patent/US10988531B2/en not_active Expired - Fee Related
- 2015-09-02 KR KR1020237007792A patent/KR102638901B1/ko active Active
- 2015-09-02 WO PCT/US2015/048044 patent/WO2016036794A1/en not_active Ceased
- 2015-09-02 AU AU2015312075A patent/AU2015312075A1/en not_active Abandoned
- 2015-09-02 KR KR1020177009020A patent/KR102508023B1/ko active Active
-
2017
- 2017-02-22 IL IL250711A patent/IL250711A0/en unknown
-
2021
- 2021-02-12 US US17/174,911 patent/US11732038B2/en active Active
-
2023
- 2023-06-28 US US18/343,455 patent/US20240190956A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017529837A5 (OSRAM) | ||
| RU2017110068A (ru) | Конъюгаты, содержащие клеточносвязывающие агенты и цитотоксические агенты | |
| JP7611218B2 (ja) | 抗ｃｄ１２３抗体、ならびにその複合体及び誘導体 | |
| JP2022191500A (ja) | フォレート受容体１抗体及びそのイムノコンジュゲート及び使用 | |
| AU2013203459B2 (en) | DLL3 modulators and methods of use | |
| CN108290949B (zh) | 对asct2具有特异性的结合分子及其用途 | |
| RU2017144859A (ru) | Конъюгаты сконструированных антител с цистеиновыми заменами | |
| AU2020414996A1 (en) | Method for producing eribulin-based antibody-drug conjugate | |
| TW202400644A (zh) | 針對ＦＲα之結合分子 | |
| US20230084099A1 (en) | Anti-meflin antibody for use in treatment of cancer in subject having cancer, and pharmaceutical composition comprising the antibody | |
| US20230310629A1 (en) | Bispecific antibody-drug conjugates targeting egfr and muc1 and uses thereof | |
| US20230183357A1 (en) | Anti-human neurotensin receptor 1 antibody and use thereof | |
| EP2281004A1 (en) | Prostate specific membrane antigen antibodies and antigen binding fragments | |
| CN120417937A (zh) | Ceacam5抗体-药物缀合物及其使用方法 | |
| US20160158380A1 (en) | Anti-Claudin 1 Antibodies for Use in the Treatment of Colorectal Cancer | |
| TW202330618A (zh) | 抗ｃｄｈ６抗體及其抗體－藥物偶聯物 | |
| CN120936386A (zh) | 核定位多肽及其缀合物及其用途 | |
| WO2024240227A1 (en) | Antibodies and antibody-drug conjugates thereof | |
| Nguyen | Development and Optimization of Antibody-Drug Conjugates for the Treatment of Acute Myeloid Leukemia | |
| KR20250172654A (ko) | Steap2 항체 약물 접합체 및 이의 용도 | |
| WO2025027554A1 (en) | Humanized muc1 antibody and antibody drug conjugate | |
| TW202432186A (zh) | 配體-細胞毒藥物綴合物及其醫藥用途 | |
| HK40082538A (en) | Method for producing eribulin-based antibody-drug conjugate | |
| HK1258317B (en) | Binding molecules specific for asct2 and uses thereof |